Royal Bank of Canada Analysts Give MorphoSys (MOR) a €65.00 Price Target
MOR has been the topic of several other reports. Independent Research set a €104.00 ($120.93) target price on MorphoSys and gave the company a neutral rating in a research note on Wednesday, November 28th. Berenberg Bank set a €108.00 ($125.58) target price on MorphoSys and gave the company a neutral rating in a research note on Thursday, February 28th. Deutsche Bank set a €125.00 ($145.35) target price on MorphoSys and gave the company a buy rating in a research note on Tuesday, January 29th. Goldman Sachs Group set a €114.00 ($132.56) price target on MorphoSys and gave the company a neutral rating in a research report on Monday, December 17th. Finally, JPMorgan Chase & Co. reiterated a buy rating on shares of MorphoSys in a research report on Wednesday, December 12th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of Hold and an average target price of €101.30 ($117.79).
Shares of MOR opened at €85.90 ($99.88) on Thursday. The firm has a market capitalization of $2.71 billion and a price-to-earnings ratio of -95.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.21 and a current ratio of 11.51. MorphoSys has a 1 year low of €76.45 ($88.90) and a 1 year high of €124.90 ($145.23).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Story: Preferred Stock
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.